Key Takeaways
- Margin story is the core thesis: EBITDA margins expanded from 8–10% to 16% in FY25 on the back of three new in-house premium excipient products, and management expects a further step-up to ~25% bottom-line margins once Unit 3 commercializes.
- Unit 3 is fully derisked on demand: Phase 1 orders are already confirmed from existing customers worldwide, and Phase 2 (MCC) will target the same customer base, making the ramp-up "much earlier" than Phase 1.
- Working capital blip, not a trend: Debtors rose because the company offered liberal payment terms to enter Indian MNC accounts in Q4; no additional working capital needs are expected for Units 1 and 2.
- Export mix is the margin lever: Export ratio is expected to improve as Unit 3 commercializes, with higher realizations in markets like the U.S., directly lifting blended margins.
- What to watch next quarter: Whether Phase 1 commercial production begins on schedule in September–October 2025, the pace of related-party transaction reduction, and any tariff developments on U.S.-bound exports.
Unit 3 Expansion: The Growth Engine
- Two-phase buildout, fully funded: Phase 1 (CCS, CMC, SSG) targets commercial production by September–October 2025; Phase 2 (MCC) follows by ~June 2026. Total capex is ~₹55 crore, with a rights issue approved up to ₹940 crores and the balance from internal accruals; management foresees no equity dilution.
- Revenue ramp is backstopped by existing customers: Phase 1 is projected at ₹70 crore in its first year (H2 FY26 only, ~6 months of operations), scaling to a peak of ₹150–160 crore by FY28 at ~45% utilization in year one, ~70% in year two, and maximum in year three. Phase 2 adds ₹220–250 crore standalone, with a faster ramp because it produces MCC for the same customer base.
- Asset efficiency is unusually high: Combined Phase 1 and Phase 2 asset-turnover ratio will not be less than 4.5 to 5 times, implying the capital deployed converts rapidly into revenue.
- Phase 2 fixes a margin leak: Currently, 2,500–3,000 metric tons of semi-finished MCC are procured externally and processed in-house to meet demand, which dilutes EBITDA margins. Once Phase 2 is operational, the company expects to eliminate this outsourcing, improving MCC margins on a like-to-like basis.
Ghanshyam Patel: "We already have orders for this amount, and we will supply the same to our existing customers worldwide."
Margin Trajectory
- The 16% base was earned through product innovation: Three new in-house products (MCG spheres, microcrystalline cellulose powder, SMCC) developed over 2–3 years by the R&D team lifted margins from 8–10% to 16% by FY25. These premium-range excipients carry realizations 3.5× to 4× that of standard MCC.
- Unit 3 promises a step-change to ~25% bottom-line: Management guided ~25% margin on a standalone basis for Unit 3, driven by premium products (CCS, CMC, SSG) with higher realizations. This is a conservative estimate, per management.
- Export mix amplifies the effect: Margins vary by country, with the U.S. market delivering higher realizations. The export ratio is expected to increase for Unit 3 and also for Units 1 and 2 compared to the reported period, lifting blended margins further.
- Raw material costs are hedged quarter-by-quarter: Wood pulp purchase prices are fixed for at least one quarter, and order books are taken only after quantity commitments with suppliers are secured. Abnormal cost increases like ocean freight are passed on to export customers.
Ghanshyam Patel: "We would then look forward to a better EBITDA margin, even from the MCC, like-to-like."
Product & Customer Evolution
- Premium products are still small but scaling: Premium-range products (CCS, MSC, etc.) currently comprise ~10% of the ₹265 crore revenue, with the balance from MCC. The product mix is changing substantially as three new excipient products enter the "More-Pro" basket sold alongside MCC.
- Indian MNCs are a new, deliberate channel: The company began selling to Indian MNCs in the last two years and offered liberal payment terms in Q4 as an entry strategy, causing the temporary working capital increase. No formal agreements are in place yet, but the channel is expected to grow.
- Customer approvals for Phase 1 are already underway: Samples and required documents have been sent to existing and new customers to secure product approvals for Phase 1's CCS, CMC, and SSG output.
- Related-party transactions are being wound down: RPTs reduced substantially in H2 FY25, and management expects them to reach negligible levels in the near future as most activities move in-house.
Current Operations & Constraints
- Both existing units are at full tilt: Unit 1 (Piranha) is at 100% utilization and Unit 2 (HSEZ) at ~95%, which is why H-unit export sales stayed flat at ~₹140.7 crore. The shortfall was compensated by increased domestic sales from the Piranha unit.
- Outsourcing is a necessary stopgap: Of the ~12,000 metric tons sold in FY25, roughly 2,500–3,000 metric tons were semi-finished goods procured externally and processed in-house using vibroshifter technology. This was done to meet a large order book and retain customers given capacity constraints, but it compresses EBITDA margins versus fully in-house manufacturing.
- Pharma dominates the customer base: 65–75% of finished goods go to pharma, ~15% to food and nutra, and 10–15% to technical grades. Margins are similar across segments domestically but vary by export market.
- No raw material or tariff disruption currently: Management sees no major change in wood pulp prices and no tariffs currently levied on its products. A contingency plan exists for potential U.S. tariffs but details were not disclosed.
Ghanshyam Patel: "At this precise moment we do not see any tariff being levied on our products or on the product we are manufacturing. But just in case if anything turns up in the future, we have a plan which we are working on, so that will be taken care of."
Regulatory & Disclosure Boundaries
- One environmental matter is on the radar: An NGT matter exists and is classified as a "remote" contingent liability by management. When asked whether all approvals for Unit 3 commencement are in hand, management stated that commercialization approvals are separate and "will not be a big task."
- Forward guidance is consistently declined: Management repeatedly cited SEBI regulations as the reason for not providing specific revenue or profit forecasts, though it offered "rough ideas" on Unit 3 revenue potential and margins to give investors insight into the order book.
- Peer comparisons are off-limits: When an analyst asked about the material cost difference versus a listed peer with better operating margins, management declined to comment, citing company policy.
- Customer names are withheld: Management declined to name the Indian MNCs added in the last 12–24 months, citing business sensitivity and the risk of details entering the public domain.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Unit 3 Phase 1 commercial production | CCS, CMC, SSG production begins | September–October 2025 |
| Unit 3 Phase 2 commercial production | MCC production begins | ~June 2026 |
| Phase 1 year-one revenue | ~₹70 crore (from ~6 months of operations in H2 FY26) | FY26 (H2) |
| Phase 1 peak revenue | ₹150–160 crore | By FY28 |
| Phase 2 standalone revenue | ₹220–250 crore | Post-Phase 2 commercialization |
| Phase 1 utilization ramp | ~45% in year 1, ~70% in year 2, maximum in year 3 | FY26–FY28 |
| Unit 3 standalone bottom-line margin | ~25% (conservative basis) | Once Unit 3 is commercialized |
| Combined asset-turnover ratio | Not less than 4.5–5× for Phase 1 + Phase 2 | Post-Phase 2 |
| Phase 2 margin improvement | Better EBITDA margins on MCC by eliminating outsourced semi-finished goods | Once Phase 2 is operational |
| Related-party transactions | Expected to reach negligible levels | Near future |
| Equity dilution | None foreseen; balance of project cost from internal accruals | Through expansion cycle |
Key Metrics
| Metric | Q4 FY25 / FY25 |
|---|---|
| Revenue from operations | ₹265 cr, +8% YoY |
| PAT | ₹33 cr, +10% YoY |
| EBITDA | +12% YoY |
| EBIT margin | Unchanged YoY |
| Operating (EBITDA) margin | 15%–16% on a consolidated basis |
| PAT margin | 12%–13% |
| Export revenue share | 53.49%, balance domestic |
| Borrowings | Significant drop compared with previous year |
| Unit-1 (Piranha) capacity utilization | 100% |
| Unit-2 (SEZ) capacity utilization | 95% |
| Combined installed capacity (Unit 1 + Unit 2) | 9,200 metric tons per annum |
| Total quantity sold in FY25 | ~12,000 metric tons (9,000 metric tons in-house manufactured, ~2,500–3,000 metric tons semi-finished goods procured and further processed) |
| Premium-range revenue share | ~10% of revenue, balance from MCC |
| Premium product realization vs MCC | 3.5× to 4× the prevailing market price of MCC |
| Unit-3 Phase 1 commercial production start | September–October 2025 |
| Unit-3 Phase 1 peak revenue | ₹150–160 cr |
| Unit-3 Phase 1 year-one revenue | ~₹70 cr (at ~45–50% utilization, ~6 months of operations) |
| Unit-3 Phase 2 commercialization | ~June 2026 |
| Unit-3 Phase 2 peak revenue | ₹220–250 cr on a standalone basis |
| Unit-3 Phase 1 capex | ~₹55 cr |
| Unit-3 Phase 2 capex | ~₹55–60 cr |
| Rights issue approval amount | Up to ₹940 cr |
| Export vs domestic margin differential | ~10% |
| Debtors-to-sales ratio | 24.52, up from 21.91 |
| Cash-conversion cycle | Increased by 10 days |
| Pharma segment share of finished goods | 65–75% |
| Food and nutra segment share | ~15% |
| Technical grades share | 10–15% |
| Contingent liability (NGT penalty) | ₹4.11 cr, classified as remote |